A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) PlusEpacadostat (INCB024360) with Platinum-based Chemotherapy Plus Placebo as First-Line Treatmentin Patients with Metastatic Non-Small Cell Lung Cancer (KN715/ECHO-306) (NCT03322566)